Evidence map›Paper›PMID 39465971›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2024

Rhesus Macaque Killer Cell Ig-like Receptor Domain 0 Glycans Impact Surface Expression and Ligand Specificity.

Jennifer L Anderson, Kjell Sandstrom, Vadim A Klenchin, David T Evans

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jennifer L AndersonDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI.
Kjell SandstromDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI.ORCID 0000-0001-5621-4137
Vadim A KlenchinDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI.
David T EvansDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI.ORCID 0000-0003-2498-6292

Funding

WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
Sustained antibody delivery for durable suppression of immunodeficiency virus replicationR01AI121135 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI David T Evans · 2015 to 2026
$6.9M
KIR and MHC Class I Immunogenetics in SIV InfectionR37AI095098 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI David T Evans · 2019 to 2026
$5.6M
Evaluation of didehydro-Cortistatin A as a block-and-lock agent for a functional HIV cure in a macaque modelR01AI167732 · NIAID · UNIVERSITY OF FLORIDA · PI David T Evans, Susana T Valente · 2021 to 2026
$4.3M
Assessing ADCC and Fc-mediated Protection against HIVR01AI148379 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T, FINZI, ANDRES · 2019 to 2023
$3.8M
Harnessing adaptive NK cell transfer to deplete viral reservoirsR01AI161816 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI BARKER, EDWARD, EVANS, DAVID T · 2021 to 2025
$3.8M
Tethering lentiviral restriction to Fc-mediated antibody responsesR01AI155163 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T · 2020 to 2024
$3.2M
KIR and MHC Class I Immunogenetics in SIV InfectionR01AI095098 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T · 2012 to 2016
$2.7M
Lentiviral Resistance to TetherinR01AI098485 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T · 2012 to 2016
$2.2M
HHS | U.S. Public Health Service (PHS) AI095098HHS | U.S. Public Health Service (PHS) AI098485HHS | U.S. Public Health Service (PHS) AI121135HHS | U.S. Public Health Service (PHS) AI148379HHS | U.S. Public Health Service (PHS) AI155163HHS | U.S. Public Health Service (PHS) AI161816NIAID NIH HHS R01 AI095098NIAID NIH HHS R01 AI098485NIAID NIH HHS R01 AI121135NIAID NIH HHS R01 AI148379NIAID NIH HHS R01 AI155163NIAID NIH HHS R01 AI161816NIAID NIH HHS R01 AI167732NIAID NIH HHS R37 AI095098NIH HHS P51 OD011106
6 · The paper itself

Abstract

Defining the MHC class I ligands of rhesus macaque killer cell Ig-like receptors (KIRs) is fundamental to NK cell biology in this species as a model for infectious diseases and comparative immunogenetics. Several rhesus macaque KIRs belong to a phylogenetically distinct group with a three-amino acid deletion in domain 0 (D0). This deletion results in polymorphic differences in potential N-linked glycosylation (PNG) sites adjacent to a predicted KIR-MHC class I contact site. Whereas most KIRs have two tandem PNG sites in D0 (N36FTN39FT), the KIRs containing the deletion only have a single site in this region (N36FT). To discern the contribution of glycosylation to KIR expression and ligand recognition, we constructed PNG mutants for six lineage II KIR genes that eliminate or create sites for N-glycan addition at these locations. The impact of these mutations on total and surface expression was determined by immunoblotting and flow cytometry. Ligand engagement was assessed by coincubating reporter cell lines bearing chimeric KIR-CD3ζ receptors with target cells expressing individual MHC class I molecules and were corroborated by staining with KIR IgG-Fc fusion proteins. We found that N36FT is glycosylated in KIR with a single site, and at least one site is glycosylated in KIRs with two tandem sites. In general, for rhesus KIRs with a single D0 glycosylation site, that site contributes to surface expression. For KIRs with two tandem sites, the first site can contribute to ligand specificity. This study establishes that D0 glycosylation of rhesus macaque KIRs modulates surface expression and contributes to ligand specificity.

Indexed as

Killer Cells, NaturalMacaca mulattaPolysaccharidesReceptors, KIRAnimalsGlycosylationHistocompatibility Antigens Class IHumansLigandsProtein DomainsHistocompatibility Antigens Class ILigandsPolysaccharidesReceptors, KIR

Identifiers

PMID39465971
PMCPMC11625459

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.